.png)
.png)
MedAnnex Ltd Receives SMART: SCOTLAND R&D Award
MedAnnex Ltd, an innovative Edinburgh-based biotechnology company developing new therapies to treat autoimmune diseases, announced today that it has been awarded up to £423,000 via the SMART: SCOTLAND programme. Alongside backing from MedAnnex’s investors, this Scottish Enterprise award will co-fund critical industrial development work for the company’s novel antibody, annexuzlimab, which has the potential to become a ground-breaking autoimmune disease therapy.
Jim Watson, Director of Innovation & Enterprise Services at Scottish Enterprise, said: “MedAnnex is a fantastic
example of an ambitious Scottish company that’s developing innovative new treatments for patients globally. This award is the latest support we’ve provided to accelerate the company’s growth plans and build its competitive advantage, and we wish the team every success.”
Dr Tina Flatau, Managing Director of MedAnnex, said: “We’re delighted that Scottish Enterprise have recognised the huge potential of modulating T-cells to treat serious autoimmune diseases and have awarded financial support for our development company in Scotland. MedAnnex’s ground-breaking annexin-A1 technology offers the potential for a completely novel class of antibody treatments, and we look forward to accelerating work to bring annexuzlimab to the clinic”.
Jim Watson, Director of Innovation & Enterprise Services at Scottish Enterprise, said: “MedAnnex is a fantastic
example of an ambitious Scottish company that’s developing innovative new treatments for patients globally. This award is the latest support we’ve provided to accelerate the company’s growth plans and build its competitive advantage, and we wish the team every success.”
Dr Tina Flatau, Managing Director of MedAnnex, said: “We’re delighted that Scottish Enterprise have recognised the huge potential of modulating T-cells to treat serious autoimmune diseases and have awarded financial support for our development company in Scotland. MedAnnex’s ground-breaking annexin-A1 technology offers the potential for a completely novel class of antibody treatments, and we look forward to accelerating work to bring annexuzlimab to the clinic”.